Daniel Chen, M.D. Ph.D.

Physician-Scientist, Cancer Immunotherapy

Daniel S. Chen, M.D., Ph.D. is a prominent figure in the field of cancer immunotherapy and biotechnology. He is currently a Partner at Genesis BioCapital and has recently launched KOMO BIOSCIENCES, the first Genesis BioCapital company and technology.3 4

Professional Background

Dr. Chen has an extensive career in oncology and immunotherapy:

He served as the Chief Medical Officer at IGM Biosciences, Inc.1 2
Prior to that, he held the position of Vice President and Global Head of Cancer Immunotherapy Development at Genentech/Roche.1 2
At Genentech/Roche, he played a crucial role in building the company's cancer immunotherapy segment and led the development of the anti-PD-L1 antibody drug Tecentriq®.2

Education and Early Career

Dr. Chen's educational background is impressive:

He received a bachelor's degree in biology from the Massachusetts Institute of Technology (1990).1
He earned both his Ph.D. in microbiology and immunology (1996) and M.D. (1998) from the University of Southern California.1
He completed his internal medicine residency and Medical Oncology Fellowship at Stanford University (2003).1
He also conducted a post-doctoral fellowship in immunology at Stanford.1

Research and Contributions

Dr. Chen has made significant contributions to the field of cancer immunotherapy:

He ran the metastatic melanoma clinic at the Stanford Cancer Center from 2003-2006.1
He studied human anti-cancer immune responses and worked on developing better immunologic tools to examine human immune responses.1
He patented the MHC cellular microarray to detect and functionally characterize antigen-specific T cell states.1

Current Endeavors

As a Partner at Genesis BioCapital, Dr. Chen is actively involved in launching new biotechnology ventures:

He recently announced the launch of KOMO BIOSCIENCES, which aims to deliver transformative advances in gene insertion technology.3 4 5

Dr. Chen's expertise in immunotherapy, oncology, and biotechnology makes him a valuable asset in the field of innovative medical research and development.